upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Health Care | Pharmaceuticals | 164.18 |
16.2
34.0
16.7
|
3-month |
0 / 11
|
|
0 / 69383
|
0.0 / 0.0 |
| 6-month |
0 / 18
|
|
0 / 88489
|
0.0 / 0.1 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director, 10% Owner | 2023-06-05 | 24.1% | 39536729 (-8.2%, NA%) | 43133868 (2023-05-24) | ||
| 14159, L.P. | Director, 10% Owner | 2016-01-08 | 12.6% | 20730548 (NA%, NA%) | () | ||
| Gray Mary Ann | Director | 2016-06-09 | 0.1% | 149476 (12.5%, NA%) | 132839 (2016-04-07) | ||
| Davis Stephen | CEO | 2024-04-09 | 0.1% | 144267 (21.4%, 49.5%) | 118842 (2024-03-27) |
C: 0 / 3
S: 0 / 49865 P: NA / 18.64 |
C: 0 / 4
S: 0 / 53597 P: NA / 19.43 |
| Hacksell Uli | CEO | 2015-02-19 | 0.1% | 115549 (0.0%, NA%) | 115549 (2015-01-16) | ||
| Baity Glenn | EVP AND GC | 2018-01-31 | 0.1% | 83734 (-30.3%, NA%) | 120292 (2018-01-11) | ||
| Stankovic Srdjan R. | President | 2022-11-22 | 0.0% | 61234 (7.7%, NA%) | 56831 (2022-10-18) | ||
| Kim Austin D. | EVP,General Counsel, Secretary | 2024-01-09 | 0.0% | 46901 (2.3%, NA%) | 45857 (2023-10-06) |
C: 0 / 1
S: 0 / 590 P: NA / 29.96 |
|
| Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | 2024-04-09 | 0.0% | 38796 (6.8%, 25.4%) | 36340 (2024-03-27) |
C: 0 / 3
S: 0 / 8332 P: NA / 18.4 |
C: 0 / 5
S: 0 / 14023 P: NA / 20.5 |
| Iversen Leslie L | Director | 2016-04-20 | 0.0% | 36127 (0.0%, NA%) | 36127 (2015-11-13) | ||
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2024-04-09 | 0.0% | 28742 (9.8%, 40.3%) | 26183 (2024-03-27) |
C: 0 / 3
S: 0 / 8922 P: NA / 18.48 |
C: 0 / 4
S: 0 / 14030 P: NA / 19.99 |
| Soland Daniel B | Director | 2023-06-05 | 0.0% | 28002 (180.0%, NA%) | 10000 (2018-03-02) | ||
| Harrigan Edmund | Director | 2023-06-05 | 0.0% | 19002 (1800.2%, NA%) | 1000 (2016-08-18) | ||
| Daly James M | Director | 2023-06-05 | 0.0% | 18002 (NA%, NA%) | 0 (2020-05-13) | ||
| Garofalo Elizabeth A. | Director | 2023-11-28 | 0.0% | 15862 (-15.4%, NA%) | 18780 (2023-06-05) | ||
| Brege Laura | Director | 2023-06-14 | 0.0% | 13502 (-24.9%, NA%) | 18002 (2023-06-05) |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-09 | 2024-04-05 | 2024-04-08 | 4 | Davis Stephen | CEO | dsp | 26574.0 | 15.55 | 1.62 | 17.87 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 144267.0
|
164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Davis Stephen | CEO | acq | 51999.0 | 30.44 | 3.17 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 170841.0
|
164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 5275.0 | 16.77 | 0.32 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 31458.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-08 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 2716.0 | 8.63 | 0.17 | 17.87 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 28742.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 5024.0 | 12.15 | 0.31 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 41364.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-08 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 2568.0 | 6.21 | 0.16 | 17.87 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 38796.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-08 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 1790.0 | 12.02 | 0.11 | 17.87 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 13100.0
|
164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 to 2024-04-07 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | acq | 3499.0 | 23.5 | 0.21 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 14890.0
|
164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-27 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 5140.0 | 12.39 | 0.31 | 17.9 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 36340.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 10048.0 | 24.22 | 0.61 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code A | 41480.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 10550.0 | 33.37 | 0.64 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code A | 31617.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-27 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 5434.0 | 17.19 | 0.33 | 17.9 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 26183.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-27 | 4 | Davis Stephen | CEO | dsp | 17714.0 | 12.97 | 1.08 | 17.9 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 118842.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Davis Stephen | CEO | acq | 34666.0 | 25.39 | 2.11 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code A | 136556.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-26 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 474.0 | 3.99 | 0.03 | 24.67 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 11391.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | acq | 840.0 | 7.08 | 0.05 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 11865.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Davis Stephen | CEO | acq | 10946.0 | 10.19 | 0.67 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 107467.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-26 | 4 | Davis Stephen | CEO | dsp | 5577.0 | 5.19 | 0.34 | 24.67 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 101890.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 1107.0 | 3.45 | 0.07 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 32056.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-26 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 624.0 | 1.95 | 0.04 | 24.67 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 31432.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 1353.0 | 6.2 | 0.08 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 21839.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-26 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 772.0 | 3.53 | 0.05 | 24.67 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 21067.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-08 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 731.0 | 2.31 | 0.04 | 29.96 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 30949.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 1287.0 | 4.06 | 0.08 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 31680.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Kim Austin D. | EVP,GENERAL COUNSEL, SECRETARY | acq | 1634.0 | 3.44 | 0.1 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 47491.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-08 | 4 | Kim Austin D. | EVP,GENERAL COUNSEL, SECRETARY | dsp | 590.0 | 1.24 | 0.04 | 29.96 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 46901.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Davis Stephen | CEO | acq | 9528.0 | 9.5 | 0.58 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 100253.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-08 | 4 | Davis Stephen | CEO | dsp | 3732.0 | 3.72 | 0.23 | 29.96 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 96521.0 | 164.18 (ACAD) |
| 2023-12-15 | 2023-12-15 | 2023-12-15 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 2000.0 | 15.36 | 0.12 | 28.3 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 11025.0 | 164.18 (ACAD) |
| 2023-11-28 | 2023-11-24 | 2023-11-24 | 4 | Garofalo Elizabeth A. | DIRECTOR | dsp | 2918.0 | 15.54 | 0.18 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code G | 15862.0 | 164.18 (ACAD) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Davis Stephen | CEO | dsp | 51999.0 | 27.27 | 3.17 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 138666.0
|
164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 5275.0 | 33.33 | 0.32 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 10551.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 5024.0 | 33.33 | 0.31 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 10048.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 to 2024-04-07 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 3499.0 | 100.0 | 0.21 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 0.0
|
164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 27460.0 | 100.0 | 1.67 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code A | 27460.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | acq | 89516.0 | 100.0 | 5.45 | 17.84 | Direct | Stock Options (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 89516.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | acq | 13964.0 | 100.0 | 0.85 | 17.84 | Direct | Stock Options (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 13964.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | acq | 8568.0 | 100.0 | 0.52 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code A | 8568.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 24714.0 | 100.0 | 1.51 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code A | 24714.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 80564.0 | 100.0 | 4.91 | 17.84 | Direct | Stock Options (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 80564.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Davis Stephen | CEO | acq | 286451.0 | 100.0 | 17.45 | 17.84 | Direct | Stock Option (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 286451.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 840.0 | 50.0 | 0.05 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 840.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Davis Stephen | CEO | dsp | 10946.0 | 50.0 | 0.67 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 10946.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 1107.0 | 50.0 | 0.07 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 1107.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 1353.0 | 50.0 | 0.08 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 1353.0 | 164.18 (ACAD) |
| 2024-02-08 | 2024-02-06 | 2024-02-06 | 4 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | acq | 25889.0 | 100.0 | 1.58 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code A | 25889.0 | 164.18 (ACAD) |
| 2024-02-08 | 2024-02-06 | 2024-02-06 | 4 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | acq | 126589.0 | 100.0 | 7.71 | 25.74 | Direct | Stock Option (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 126589.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 1287.0 | 100.0 | 0.08 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 0.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Kim Austin D. | EVP,GENERAL COUNSEL, SECRETARY | dsp | 1634.0 | 100.0 | 0.1 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 0.0 | 164.18 (ACAD) |
| 2024-01-09 | 2024-01-06 | 2024-01-06 | 4 | Davis Stephen | CEO | dsp | 9528.0 | 100.0 | 0.58 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 0.0 | 164.18 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-17 | 4 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | dsp | 3964.0 | 33.32 | 0.24 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 7931.0
|
164.18 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 9912.0 | 33.33 | 0.6 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 19826.0
|
164.18 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-17 | 4 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | dsp | 9912.0 | 33.33 | 0.6 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 19826.0
|
164.18 (ACAD) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)